Royalty Pharma plc

As of September 30, 2026, Royalty Pharma plc carries a market capitalization of 26.02B, placing it among publicly traded companies globally. Its enterprise value stands at 36.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Royalty Pharma plc's next confirmed earnings release is scheduled for February 16, 2027.

As of September 30, 2026, Royalty Pharma plc has 445.82M shares outstanding.

As of September 30, 2026, Royalty Pharma plc trades at a trailing price-to-earnings ratio of 38.17. The price-to-sales ratio is 9.79, and the price-to-book ratio stands at 3.81.

As of September 30, 2026, Royalty Pharma plc trades at an EV/EBITDA multiple of 24.05 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 13.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 24.13 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Royalty Pharma plc trades at an EV/FCF ratio of 10.83, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 36.08B versus a market cap of 26.02B, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2026, Royalty Pharma plc maintains a current ratio of 1.29, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 87.67, indicating elevated leverage, while an interest coverage ratio of 4.03 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended September 30, 2026, Royalty Pharma plc posted a return on equity (ROE) of 10.13, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.09 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.46, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.94, useful for judging operating efficiency across full business cycles. The company generates approximately 26.17M in revenue per employee across its workforce of 100.00, a quick read on workforce productivity versus industry peers.

As of the close on November 6, 2026, Royalty Pharma plc's stock has gained approximately 65.03% over the past 52 weeks. The 50-day moving average sits at 60.82, while the 200-day moving average is 53.91.

Over the twelve months ended September 30, 2026, Royalty Pharma plc generated 2.62B in revenue and converted that into 671.45M in net income, yielding earnings per share of 2.11. EBITDA reached 1.50B, while operating income came in at 1.72B.

As of September 30, 2026, Royalty Pharma plc holds 1.48B in cash and equivalents against 8.59B in total debt, resulting in a net debt position of 8.07B. Total book value stands at 6.84B, with working capital of 346.56M providing operational flexibility.

Royalty Pharma plc produced 2.96B in operating cash flow over the twelve months ended September 30, 2026.

These figures cover the twelve months ended September 30, 2026. The operating margin of 65.54 and net profit margin of 25.66 provide insight into operational efficiency.

Over the twelve months ended September 30, 2026, Royalty Pharma plc paid dividends of 0.93 per share. The dividend payout ratio of 24.44 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 9.11, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.93, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Royalty Pharma plc shareholders.

As of September 30, 2026, Royalty Pharma plc has an Altman Z-Score of 2.27, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.